Duncker Streett & Co. Inc. Sells 1,270 Shares of Becton, Dickinson and Company (NYSE:BDX)

Duncker Streett & Co. Inc. lessened its holdings in Becton, Dickinson and Company (NYSE:BDX) by 44.3% in the 4th quarter, Holdings Channel reports. The firm owned 1,595 shares of the medical instruments supplier’s stock after selling 1,270 shares during the quarter. Duncker Streett & Co. Inc.’s holdings in Becton, Dickinson and Company were worth $362,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Tompkins Financial Corp lifted its holdings in shares of Becton, Dickinson and Company by 44.2% during the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 46 shares in the last quarter. Radnor Capital Management LLC lifted its holdings in shares of Becton, Dickinson and Company by 1.7% during the 3rd quarter. Radnor Capital Management LLC now owns 2,937 shares of the medical instruments supplier’s stock valued at $708,000 after purchasing an additional 48 shares in the last quarter. Wesbanco Bank Inc. lifted its holdings in shares of Becton, Dickinson and Company by 1.9% during the 4th quarter. Wesbanco Bank Inc. now owns 2,558 shares of the medical instruments supplier’s stock valued at $580,000 after purchasing an additional 48 shares in the last quarter. Umpqua Bank lifted its holdings in shares of Becton, Dickinson and Company by 1.8% during the 3rd quarter. Umpqua Bank now owns 2,738 shares of the medical instruments supplier’s stock valued at $660,000 after purchasing an additional 49 shares in the last quarter. Finally, Americana Partners LLC lifted its holdings in shares of Becton, Dickinson and Company by 3.5% during the 3rd quarter. Americana Partners LLC now owns 1,468 shares of the medical instruments supplier’s stock valued at $354,000 after purchasing an additional 50 shares in the last quarter. Institutional investors and hedge funds own 86.97% of the company’s stock.

Becton, Dickinson and Company Stock Up 0.6 %

BDX stock opened at $225.57 on Monday. The company has a current ratio of 1.13, a quick ratio of 0.63 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $64.77 billion, a PE ratio of 37.47, a PEG ratio of 1.63 and a beta of 0.40. Becton, Dickinson and Company has a 1-year low of $218.75 and a 1-year high of $251.99. The business’s 50 day simple moving average is $233.08 and its 200 day simple moving average is $233.02.

Becton, Dickinson and Company (NYSE:BDX) last posted its earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, topping analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a return on equity of 15.74% and a net margin of 8.47%. As a group, research analysts anticipate that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company declared that its Board of Directors has approved a share buyback program on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 outstanding shares. This repurchase authorization authorizes the medical instruments supplier to buy shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company’s board believes its shares are undervalued.

Becton, Dickinson and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be given a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 1.84%. The ex-dividend date is Monday, March 10th. Becton, Dickinson and Company’s payout ratio is 69.10%.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP Roland Goette sold 638 shares of the stock in a transaction on Monday, December 9th. The stock was sold at an average price of $219.03, for a total transaction of $139,741.14. Following the transaction, the executive vice president now owns 14,217 shares in the company, valued at $3,113,949.51. This trade represents a 4.29 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Jeffrey William Henderson acquired 1,500 shares of the stock in a transaction on Monday, February 10th. The shares were purchased at an average price of $233.62 per share, for a total transaction of $350,430.00. Following the transaction, the director now directly owns 8,015 shares in the company, valued at approximately $1,872,464.30. This trade represents a 23.02 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have sold 10,544 shares of company stock worth $2,370,309 in the last 90 days. Company insiders own 0.36% of the company’s stock.

Analysts Set New Price Targets

BDX has been the topic of several research reports. Piper Sandler boosted their target price on Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a research note on Tuesday, January 28th. StockNews.com cut Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Tuesday, February 25th. Finally, Barclays boosted their target price on Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat, Becton, Dickinson and Company has an average rating of “Moderate Buy” and a consensus price target of $278.29.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.